Paroxysmal Nocturnal Hemoglobinuria Market Enters Transition Phase as Second-Line Opportunities Expand Amid Ongoing Barriers to Adoption of Newer Agents, According to Spherix Global Insights
Recently released data finds 22% of patients are not optimally managed despite growing use of Novartis’ Fabhalta, Alexion’s Voydeya, and Roche’s PiaSky Exton, PA., March 5, 2026 — Spherix Global Insights today announces the release of its latest Market Dynamix™: Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for […]
Otsuka Pharmaceutical’s VOYXACT Gains Early Traction in IgAN, with 21% of Nephrologists Reporting Prescribing Within Two Months of Approval
Strong clinical advance perceptions and anticipated displacement of other IgAN-targeted therapies position Voyxact for meaningful early momentum, according to the latest findings from Spherix Global Insights. Exton, PA., February 24, 2026 — Two months following the U.S. approval of Voyxact (sibeprenlimab) for IgA nephropathy (IgAN), new data from Spherix Global Insights indicate rapid early uptake and […]
Spherix Global Insights Reveals Persistent High Disease Burden and Heavy Reliance on Pain Management in U.S. Sickle Cell Disease Despite Awareness of Disease-Modifying Therapies
New Patient Voice Dynamix™ research highlights that even with patients’ high awareness of options and active engagement in their care, systemic barriers and personal limitations from ongoing severe pain keep many patients from experiencing optimal disease control. Exton, PA., February 5, 2026 — New research from Spherix Global Insights underscores the profound and multifaceted burden […]